News

Novo Nordisk’s Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...
Novo Nordisk: The Market Has Lost Its Mind
While Novo Nordisk has gotten a lot of attention for its obesity/weight-loss drug Wegovy in recent years, Novo Nordisk is ...
Wegovy maker Novo Nordisk to cut costs as competition grows
Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...
Novo Nordisk, TSMC, Glencore: Stocks Around the World in Focus
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies
Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...
Why Novo Nordisk Stock Slipped Today
Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...
Marketplace1d
Makers of Wegovy, Zepbound face competition from compounding pharmacies
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.